Zeria Pharmaceutical Co., Ltd. (TYO:4559)
Japan
· Delayed Price · Currency is JPY 2,068.00
-3.00 (-0.14%)
Jun 12, 2025, 3:30 PM JST
Zeria Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 23,592 | 20,323 | 16,219 | 11,704 | 9,793 | Upgrade
|
Short-Term Investments | - | - | - | - | 3 | Upgrade
|
Cash & Short-Term Investments | 23,592 | 20,323 | 16,219 | 11,704 | 9,796 | Upgrade
|
Cash Growth | 16.09% | 25.30% | 38.58% | 19.48% | 8.78% | Upgrade
|
Receivables | 26,611 | 21,080 | 17,419 | 16,153 | 13,497 | Upgrade
|
Inventory | 16,433 | 14,489 | 12,764 | 11,950 | 11,104 | Upgrade
|
Other Current Assets | 2,893 | 1,917 | 1,801 | 1,856 | 2,916 | Upgrade
|
Total Current Assets | 69,529 | 57,809 | 48,203 | 41,663 | 37,313 | Upgrade
|
Property, Plant & Equipment | 26,641 | 26,517 | 24,591 | 23,139 | 23,634 | Upgrade
|
Long-Term Investments | 22,541 | 22,957 | 20,172 | 18,165 | 18,775 | Upgrade
|
Goodwill | 3,621 | 4,262 | 5,299 | 5,830 | 6,429 | Upgrade
|
Other Intangible Assets | 36,740 | 38,877 | 36,631 | 35,376 | 35,640 | Upgrade
|
Long-Term Deferred Tax Assets | 97 | 110 | 136 | 108 | 67 | Upgrade
|
Other Long-Term Assets | 2 | 1 | 2 | 1 | 1 | Upgrade
|
Total Assets | 159,171 | 150,533 | 135,034 | 124,282 | 121,859 | Upgrade
|
Accounts Payable | 3,971 | 3,273 | 1,996 | 2,049 | 1,693 | Upgrade
|
Accrued Expenses | 1,623 | 1,584 | 1,554 | 1,530 | 1,268 | Upgrade
|
Short-Term Debt | 34,298 | 38,283 | 34,890 | 33,842 | 44,158 | Upgrade
|
Current Income Taxes Payable | 3,773 | 1,967 | 749 | 458 | 562 | Upgrade
|
Other Current Liabilities | 10,784 | 9,411 | 7,969 | 6,314 | 6,076 | Upgrade
|
Total Current Liabilities | 54,449 | 54,518 | 47,158 | 44,193 | 53,757 | Upgrade
|
Long-Term Debt | 6,865 | 7,943 | 14,541 | 18,385 | 5,819 | Upgrade
|
Long-Term Deferred Tax Liabilities | 6,496 | 6,447 | 5,190 | 3,905 | 3,356 | Upgrade
|
Other Long-Term Liabilities | 1,341 | 1,339 | 2,232 | 1,635 | 1,441 | Upgrade
|
Total Liabilities | 69,375 | 70,705 | 69,355 | 69,191 | 65,681 | Upgrade
|
Common Stock | 6,593 | 6,593 | 6,593 | 6,593 | 6,593 | Upgrade
|
Additional Paid-In Capital | 11,685 | 11,685 | 11,685 | 11,685 | 11,685 | Upgrade
|
Retained Earnings | 67,207 | 59,254 | 53,462 | 48,860 | 46,380 | Upgrade
|
Treasury Stock | -18,266 | -18,265 | -18,264 | -17,593 | -14,997 | Upgrade
|
Comprehensive Income & Other | 22,320 | 20,355 | 11,973 | 5,349 | 6,350 | Upgrade
|
Total Common Equity | 89,539 | 79,622 | 65,449 | 54,894 | 56,011 | Upgrade
|
Minority Interest | 257 | 206 | 230 | 197 | 167 | Upgrade
|
Shareholders' Equity | 89,796 | 79,828 | 65,679 | 55,091 | 56,178 | Upgrade
|
Total Liabilities & Equity | 159,171 | 150,533 | 135,034 | 124,282 | 121,859 | Upgrade
|
Total Debt | 41,163 | 46,226 | 49,431 | 52,227 | 49,977 | Upgrade
|
Net Cash (Debt) | -17,571 | -25,903 | -33,212 | -40,523 | -40,181 | Upgrade
|
Net Cash Per Share | -398.62 | -587.64 | -751.86 | -897.74 | -872.14 | Upgrade
|
Filing Date Shares Outstanding | 44.08 | 44.08 | 44.08 | 44.21 | 45.36 | Upgrade
|
Total Common Shares Outstanding | 44.08 | 44.08 | 44.08 | 44.41 | 45.7 | Upgrade
|
Working Capital | 15,080 | 3,291 | 1,045 | -2,530 | -16,444 | Upgrade
|
Book Value Per Share | 2031.31 | 1806.31 | 1484.77 | 1236.08 | 1225.66 | Upgrade
|
Tangible Book Value | 49,178 | 36,483 | 23,519 | 13,688 | 13,942 | Upgrade
|
Tangible Book Value Per Share | 1115.67 | 827.66 | 533.55 | 308.22 | 305.09 | Upgrade
|
Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.